NATICK, Mass., Aug. 27 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and news announcements for the European Society of Cardiology (ESC) Congress, which runs from August 29 to September 2 in Barcelona. Highlights include final results from the MADIT-CRT trial and two-year results from the SYNTAX trial.
"Boston Scientific is proud to be the exclusive sponsor of the landmark MADIT-CRT trial, and we look forward to the presentation of the final data at ESC," said Ray Elliott, President and Chief Executive Officer of Boston Scientific. "MADIT-CRT is breaking new ground by demonstrating that early intervention with cardiac resynchronization defibrillation therapy (CRT-D) slows the progression of heart failure when compared to standard implantable cardioverter defibrillator (ICD) therapy. We are also looking forward to the presentation of two-year data from our SYNTAX trial, comparing the use of percutaneous coronary intervention (PCI) using the TAXUS(R) Express2(R) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery in patients with complex disease. We are hopeful these results will build on the one-year data, which showed comparable safety outcomes for PCI and CABG."
Details of the Company's activities at ESC are below.
Schedule of Events (All times are local Barcelona; all events are held at the Fira Gran Via Convention Center.)
Sunday, August 30
Monday, August 31
Tuesday, September 1
Wednesday, September 2
Boston Scientific will present its latest innovations at booth C99 in the Exhibition Hall. Cardiovascular and cardiac rhythm management products will include the LATITUDE(R) Patient Management System, which was recently launched in Europe, and the Company's third-generation drug-eluting stents: the TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System and the PROMUS(R) Element(TM) Everolimus-Eluting Coronary Stent System.
The Company is still expecting CE Mark approval and launch for both the TAXUS Element and the PROMUS Element Stent Systems in the fourth quarter of this year. The TAXUS Element and PROMUS Element Stent Systems are not available for sale in the United States.
The safety and effectiveness of the TAXUS(R) Express(R) Stent has not been established in patients with left main or three-vessel disease.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
CONTACT: Paul Donovan 508-650-8541 (office) 508-667-5165 (mobile) Media Relations Boston Scientific Corporation Larry Neumann 508-650-8696 (office) Investor Relations Boston Scientific Corporation
|SOURCE Boston Scientific Corporation|
Copyright©2009 PR Newswire.
All rights reserved